| Is a new therapeutic class justified in the treatment of type 2 diabetes? | |
| | |
MedLine Citation:
|
PMID: 12037511 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Type 2 diabetes is responsible for various micro and macro-vascular complications, appearing early in the course of the disease. The UKPDS results clearly demonstrate the interest of an early and intensive treatment of hyperglycaemia to reduce theses microvascular complications and, to a lesser extent, macrovascular complications. The UKPDS also demonstrate the limits of the current management of type 2 diabetes: delayed diagnosis when several complications already exist, difficulties to maintain an adequate glucose control over the time, particularly with monotherapy, need for an intensive combination treatment policy, unwanted effects of this intensive treatment (weight gain, hypoglycaemias). The 3 classes of oral antidiabetic agents currently available (sulfonylureas and meteglinide analogues, metformin, a-glucosidase inhibitors) imperfectly cover the current therapeutic needs. Thus, the new class, the thiazolidinediones, acting on key physiopathological components, appears as a welcome addition to the treatment of type 2 diabetes. The association of metformin (or a sulfonylurea) and a thiazolidinedione should permit to obtain early a better glycaemic control without the hypoglycaemic risk associated with intensive therapy at an early stage of type 2 diabetes. |
| | |
Authors:
|
S Halimi |
Publication Detail:
|
Type: English Abstract; Journal Article; Review |
Journal Detail:
|
Title: Annales d'endocrinologie Volume: 63 ISSN: 0003-4266 ISO Abbreviation: Ann. Endocrinol. (Paris) Publication Date: 2002 Apr |
Date Detail:
|
Created Date: 2002-05-30 Completed Date: 2002-07-31 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0116744 Medline TA: Ann Endocrinol (Paris) Country: France |
Other Details:
|
Languages: fre Pagination: 1S7-11 Citation Subset: IM |
Affiliation:
|
Service d'Endocrinologie - Diabétologie - Nutrition, CHU de Grenoble, F - 38043 Grenoble Cedex, France. |
Vernacular Title:
|
Une nouvelle classe thérapeutique se justifie-t-elle dans le traitement du diabète de type 2? |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Oral Diabetes Mellitus, Type 2 / complications, therapy* Drug Therapy, Combination Humans Hypoglycemic Agents / therapeutic use* Metformin / administration & dosage, therapeutic use Thiazoles / chemistry, therapeutic use* Thiazolidinediones* |
| Chemical | |
Reg. No./Substance:
|
0/Hypoglycemic Agents; 0/Thiazoles; 0/Thiazolidinediones; 2295-31-0/2,4-thiazolidinedione; 657-24-9/Metformin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Precautions for use and contraindications of thiazolidinediones. A cardiologist opinion
Next Document: Thalamocortical [correction of Thalamcortical] optimization of tactile processing according to behav...